Sandoz, the Swiss maker of generic drugs and biosimilars, is set to hold its capital markets day on September 8. Investors are hoping the event will offer more than a rehash of the company's existing targets. According to analysts at RBC, the market is looking for a clearer picture of what growth will look like after 2028, especially in light of a recent partnership with China's Henlius.
What is Sandoz and why does this matter?
Sandoz was spun off from Novartis in 2023 to focus on generics and biosimilars. Generics are copies of brand-name drugs that have lost patent protection, while biosimilars are near-identical versions of biologic medicines, which are made from living cells and are far more complex to replicate. Biosimilars are a key growth area for the company, as many expensive biologic drugs are set to lose patent protection in the coming years.
The capital markets day is an event where company executives present their strategy and financial targets to investors and analysts. It is a chance for management to lay out where they see the business heading and to reassure shareholders that the company has a solid plan for the future.
The Henlius partnership and what it means
Earlier this year, Sandoz announced a partnership with Henlius, a Chinese biopharmaceutical company. The deal is aimed at expanding Sandoz's biosimilar pipeline, giving it access to Henlius's development capabilities and potentially speeding up the launch of new products. RBC notes that this partnership could be central to the new targets Sandoz presents at the capital markets day.
For investors, the key question is how quickly Sandoz can bring these biosimilars to market. Biosimilar launches are complex and face regulatory hurdles, so clear timelines are crucial. RBC suggests that the capital markets day could provide more specific launch dates, which would help investors gauge the company's near-term revenue potential.
Why investors want more than a rehash
Sandoz has already set midterm targets, but those may not extend far enough. With the Henlius partnership, the company has new growth levers, but it needs to show how those will translate into earnings. Investors are also watching the broader market for biosimilars, which is becoming increasingly competitive. Companies like Amgen, Pfizer, and Samsung Bioepis are all vying for market share.
RBC's note suggests that the market is looking for a fresh set of targets that incorporate the Henlius deal and provide a roadmap for growth beyond 2028. This could include updated revenue forecasts, margin expectations, or a more detailed pipeline timeline.
What it means for investors
For everyday investors, the capital markets day is a chance to see whether Sandoz's management can deliver on its promises. If the company presents credible, ambitious targets, it could boost confidence in the stock. On the other hand, if the event feels like a repeat of previous guidance, investors may be disappointed.
It's also worth noting that Sandoz operates in a sector that is sensitive to regulatory changes and pricing pressures. Governments and insurers are increasingly pushing for lower drug prices, which could squeeze margins. The Henlius partnership is partly a response to these pressures, as it aims to lower development costs and speed up time to market.
Investors should also keep an eye on the broader market context. China's stock market has been volatile, and the Henlius partnership ties Sandoz's fortunes to a Chinese partner. Any geopolitical or regulatory shifts could affect the collaboration.
What to watch next
At the September 8 event, investors will be listening for several things: updated midterm financial targets, specific biosimilar launch dates, and any commentary on the competitive landscape. RBC's note suggests that the company needs to show it has a clear plan to grow after 2028, not just a continuation of current trends.
For those who own Sandoz shares or are considering them, the capital markets day could be a catalyst. But as always, it's important to remember that events like this are just one piece of the puzzle. The company's long-term success will depend on its ability to execute on its strategy and navigate a challenging market.
In the meantime, investors can also look at how Sandoz's peers are performing. The broader pharmaceutical sector is facing headwinds from patent expirations and pricing pressures, but also opportunities from new drug launches and partnerships. Sandoz's ability to capitalize on those opportunities will be key.
As the date approaches, expect more commentary from analysts and possibly some pre-announcements from the company. But for now, the message from RBC is clear: investors want substance, not just a rehash of old goals.
